Iovance Biotherapeutics Inc. Common Stock vs Viasat — how do they compare? Iovance Biotherapeutics Inc. Common Stock trades at $14.43 (market cap $6.04B), while Viasat trades at $72.54 (market cap $9.29B). The key difference: Viasat is the larger of the two by market cap, and Iovance Biotherapeutics Inc. Common Stock is trading nearer its 52-week high, Viasat nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Iovance Biotherapeutics Inc. Common Stock for 0 Days and Viasat for 10 Days on average.
| IOVA | VSAT | |
|---|---|---|
Market Cap | $6.04B | $9.29B |
Volume | 14,805,993 | 2,084,105 |
Sector | Health | Technology |
52-Week High | $14.82 | $89.81 |
52-Week Low | $1.81 | $30.35 |
Typical Hold Time | 0 Days | 10 Days |
Enterprise Value | $5.97B | $14.48B |
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Iovance Biotherapeutics develops cell therapies for cancer. Its approach uses tumor-infiltrating lymphocytes, or TIL, to target solid tumors.
Read more on IOVA →Viasat provides satellite communications and connectivity services for aviation, maritime, government, enterprise, and consumer markets. Its network combines satellite and ground infrastructure to deliver connectivity in remote and mobile environments.
Read more on VSAT →